SOLV - Solventum Forward P/S Multiple

Symbol and logo of brand Solventum Inc. (SOLV)

Strict FDA oversight and lobbying create significant barriers to entry for new players, yet Solventum Corporation (SOLV) robotic lines minimize labor costs. The company's forward P/S valuation on the GURU.Markets chart resolves this contrast, with the value fixed at 0.20. Business stability relies on a massive patent portfolio, which makes switching medical consumables virtually impossible.

SOLV Solventum Corp: Market Cap to Projected Revenue in the range 03/01/2025 - 11/14/2026

Metric breakdowns and analytics for solventum.com (SOLV)

- stock price and consensus target price:
Stock Quotes Solventum Inc.|SOLV - Price Target Chart
- market capitalization statistics:
Market Capitalization Solventum Health|SOLV - Total Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Solventum|SOLV - Accounting Capitalization|Market Cap to Net Assets Ratio solventum.com|SOLV - Aggregate Business Assets
- debt and liquidity data:
Total Debt to Equity Ratio Solventum Corporation|SOLV - Long-Term Debt to Capital|Short-Term Debt to Equity Solventum Corp|SOLV - Company Total Debt|Debt to Book Value Solventum Corp|SOLV - Company Long-Term Loans and Borrowings|Company Short-Term Debts Solventum|Quick Liquidity solventum.com
- business earnings and investment ratios data:
SOLV - Company Net Income|Expected Profit Solventum Corporation|SOLV - Company Value to Net Income|Future Price to Earnings Solventum Inc.|SOLV - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Solventum Health|SOLV - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Solventum|SOLV - Earnings per share for the trailing year|Quarterly EPS earnings growth solventum.com|SOLV - Earnings growth in current year|Expected earnings per share growth for next year Solventum Corporation
- sales and revenue indicators:
SOLV - Company Total Sales|Projected Sales Volume Solventum Health|SOLV - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Solventum Health
Analysis of all company metrics:Solventum Inc. (SOLV)
Manufactured products of Solventum Corporation

Solventum Corporation (SOLV) maintains resilience against market downturns due to stable clinic demand for proven medical consumables. Regular multi-million dollar procurements of core products create a predictable cash flow, reducing business volatility. By analyzing the forward P/S multiple, an investor assesses the company's current valuation relative to expected revenue to determine if the asset is overbought based on Wall Street consensus forecasts.

Key competitors

Forward P/S Multiple HCA (HCA Healthcare, Inc.)|Price to Expected Revenue Ratio THC (Tenet Healthcare)|FMS - Price-to-Projected Revenue Ratio|Future Price to Revenue EHC|Universal Health Services (UHS) - Price-to-Projected Revenue Ratio|DaVita - Forward Price to Sales|Forward Price-to-Revenue Multiple RDNT|OPCH: Forward Price to Sales|Forward Price-to-Revenue Multiple SGRY (Surgery Partners, Inc.)|PINC (Premier, Inc.) - Forward Price to Sales|National Vision - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Progyny Inc (PGNY)|Ardent Health - Forward P/S Multiple|Market Cap to Expected Sales Ratio Select Medical Corp SEM|ASTH: Forward P/S Multiple|Market Cap to Projected Revenue MD|USPH (US Physical Therapy Inc) - Forward P/S Multiple|PNTG: Forward Price to Sales|Price-to-Projected Revenue Ratio Organogenesis Corp (ORGO)|NUTX (Nutex Health Corp) - Forward Price to Sales|Forward P/S Multiple AUNA (Auna S.A.)|SBC Medical Group Holdings Inc (SBC) - Market Cap to Future Revenue Ratio|EOLS - Price-to-Projected Revenue Ratio|Forward Price to Sales CYH (Community Health Systems Inc)|SKIN (beautyhealth.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue MDWD|Price-to-Projected Revenue Ratio biote Corp.|Market Cap to Future Revenue Ratio thejoint.com JYNT|Forward P/S Multiple DCGO|Forward Price-to-Revenue Multiple P3 Health PIII|Forward P/S Multiple GANX (Gain Therapeutics Inc.)|Forward P/S Multiple EUDA Health Holdings Limited EUDA|baselmedical.com - Forward P/S Multiple|CLGN: Price-to-Projected Revenue Ratio|Cuprina Holdings (Cayman) Ltd. (CUPR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Concord Medical|AMS (American Shared Hospital Services Inc) - Forward P/S Multiple|MEDIROM Corp (MRM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALBT|Market Cap to Expected Sales Ratio DIH Holding|Forward P/S Multiple XAGE (carmellcosmetics.com)|NIVF: Market Cap to Projected Revenue|ATIP: Forward Price-to-Revenue Multiple|CareMax Medical Group - Price to Expected Revenue Ratio|Kindly MD (KDLY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MODV|Price-to-Projected Revenue Ratio Novo Integrated Sciences Corp|Market Cap to Future Revenue Ratio SunLink Health Systems SSY|Price-to-Projected Revenue Ratio IMAC Corp (BACK)